EUCTR2021-000150-26-DE进行中（未招募）1 期
Phase IIA trial of short-term chemotherapy and pembrolizumab, followed by Pembrolizumab and Olaparib as firstline therapy in Her-2 negative gastric/gastroesophageal-junction (GEJ) Adenocarcinoma – POLESTAR – - POLESTAR
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 31
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Metastatic or unresectable, histologically confirmed Her-2 negative (as assessed locally by a certified test) adenocarcinoma of the gastroesophageal junction (AEG I-III according to Sievert´s classification) or the stomach.
- •2.Adjuvant/neoadjuvant or perioperative chemotherapy or chemoradiotherapy must have been finished at least 6 months before start of the study intervention.
- •3.Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.
- •4.Ability for oral intake of the study drug.
- •5.Male/female* participants who are at least 18 years of age on the day of signing informed consent with histologically confirmed diagnosis of esophagogastric adenocarcinoma will be enrolled in this study.
- •*There are no data that indicate special gender distribution. Therefore, patients will be enrolled in the study gender-independently.
- •6.Male participants: A male participant must agree to use a contraception as detailed in Appendix 3 of this protocol during the treatment period and for at least 6 months after the last dose of study intervention and refrain from donating sperm during this period.
- •7.Female participants: A female participant is eligible to participate if she is not pregnant (see Appendix 3), not breastfeeding, and at least one of the following conditions applies:
- •a.Not a woman of childbearing potential (WOCBP) as defined in Appendix 3
- •b.A WOCBP who agrees to follow the contraceptive guidance as given in Appendix 3 during the treatment period and for at least 6 months after the last dose of study intervention.
- •8.The participant provides written informed consent for the trial.
- •9.Have measurable or evaluable disease based on RECIST 1.1. Lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions.
- •10.Have provided archival tumor tissue sample. FFPE tissue blocks are preferred to slides.
- •11.Have adequate organ function as defined in protocol. Specimens must be collected within 14 days prior to the start of study intervention.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 15
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 16
排除标准
- •1.A WOCBP who has a positive urine pregnancy test within 72 hours prior to start of study intervention. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
- •2.Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti PD L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g., CTLA-4, OX 40, CD137) or with a PARP inhibitor, including Olaparib.
- •3.Has received prior systemic anti-cancer therapy for metastatic or locally advanced (irresectable) disease. A prior neoadjuvant or adjuvant chemotherapy is allowed
- •4.Persistent clinically relevant toxicities, CTCAE Grade > 2 caused by previous cancer treatment.
- •5.Has received prior radiotherapy within 2 weeks of start of study intervention. Participants must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis. A 1-week washout is permitted for palliative radiation (= 2 weeks of radiotherapy) to non-CNS disease.
- •6.Participant received colony-stimulating factors within 28 days prior to the first dose of study intervention
- •7.Participant is unable to swallow orally administered medication or has a gastrointestinal disorder affecting absorption.
- •8.Major surgery within 2 weeks of starting study intervention and patients must have recovered from any effects of any major surgery.
- •9.Participant is currently receiving either strong or moderate inhibitors of cytochrome P450 (CYP)3A4 that cannot be discontinued for the duration of the study. The required washout period prior to starting olaparib is 2 weeks.
- •10.Participant is currently receiving either strong or moderate inducers of CYP3A4 that cannot be discontinued for the duration of the study.
- •11.Concomitant use of drugs inhibiting DPD activity
- •12.Resting ECG indicating uncontrolled, potentially reversible cardiac conditions, as judged by the investigator, or patients with congenital long QT syndrome.
- •13.Has received a live vaccine or live-attenuated vaccine within 30 days prior to the first dose of study drug. Administration of killed vaccines is allowed.
- •14.Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study intervention.
- •15.Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drug.
- •16.Has a known additional malignancy that is progressing or has required active treatment within the past 2 years. Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin or carcinoma in situ that have undergone potentially curative therapy are not excluded.
- •17.Participant has MDS/AML
- •18.Has known active CNS metastases and/or carcinomatous meningitis. Participants with previously completely resected brain metastases may participate if there is no sign of progression for at least 4 weeks by repeat imaging clinically stable and without requirement of steroid treatment for at least 14 days prior to first dose of study intervention.
- •19.Has severe hypersensitivity (= Grade 3) to FOLFOX or CAPOX-based chemotherapy, olaparib, pembrolizumab and/or any of its excipients.
- •20.Known DPD deficiency. Patients with a reduced DPD activity (CPIC activity score of 1.0-1.5) might participate in the study and receive a reduced
研究者
相似试验
招募中
2 期
Phase II study of combination chemotherapy using paclitaxel, carboplatin, and bevacizumab in patients with advanced or recurrent cervical cancer.cervical cancerJPRN-UMIN000024137Hyogo Cancer Center30
进行中（未招募）
不适用
A phase II study of primary chemotherapy with pegylated liposomal doxorubicin (Caelyx), Cisplatin, and Fluorouracil (CCF) followed by metronomic Capecitabine, Cyclophosphamide and Sorafenib (CCS) in early and locally advanced, ?triple negative? breast cancer - NDPatients with histologically proven locally advanced primary breast cancer (cT2-T3-T4 a-d, N0-3c, M0) or patients with histologically proven local recurrence after breast conserving surgery (rT1-T4, N0-3c, M0, triple negative (absence of ER, PgR and c-erbB2 expression)MedDRA version: 9.1Level: LLTClassification code 10057654Term: Breast cancer femaleEUCTR2007-006306-25-ITISTITUTO EUROPEO DI ONCOLOGIA
招募中
2 期
Phase II study of elental for chemotherapy induced mucositis oral and nutritional disturbanceJPRN-UMIN000009298Aizawa Hospital30
招募中
1 期
Phase I/II trial of combination chemotherapy using TS-1, CPT-11 and cetuximab with radiation in locally advanced rectal cancerRectal cancerJPRN-UMIN000002602Yokohama City University Graduate School of Medicine35
进行中（未招募）
不适用
Phase II study to evaluate the efficacy of a chemotherapy combination with Imatinib (Glivec®) and 5-FU/leucovorin in patients with advanced carcinoma of the gallbladder and bile duct - TUD-Glivec-012advanced carcinoma of the gallbladder and bile ductEUCTR2006-003451-20-DETechnical University Dresden44